AbCellera Biologics, Inc. ABCL 深 滬
交易中 04-30 10:21:01 美东时间
3.855
+0.035
+0.92%
華盛通- 最 高3.935
- 今 開3.88
- 成交量 67.76万股
- 最 低 3.825
- 昨 收 3.82
- 總市值 11.69亿
- 52周最高 6.515
- 市盈率 靜 --
- 換手率 0.22%
- 52周最低 1.94
- 委 比 -16.77%
- 總股本 3.03亿
- 歷史最高 71.91
- 量 比 0.69
- 振 幅 2.88%
- 歷史最低 1.8906
- 每 手 1
- 風險率 0.94%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多AbCellera To Disclose Interim Results From Phase 1 Portion Of Its Study Of ABCL635, Including Observed Safety Profile, Pharmacokinetic, And Pharmacodynamic Target Engagement Data, During Q1 Earnings Call On May 11
AbCellera (NASDAQ:ABCL) today announced that it will disclose interim results from the Phase 1 portion of its study of ABCL635, including observed safety profile, pharmacokinetic, and pharmacodynamic target engagement
04-20 21:06
美股大行评级 | 大砍54%！大摩下调Robinhood 目标价从147降至95美元；星座品牌酒业(STZ)获8家大行上调目标价
今日重点评级关注：Ascendiant Capital：维持Allarity Therapeutics"买入"评级，目标价从9.5美元升至9.75美元；Citizens：维持戴夫"跑赢大市"评级，目标价从310美元升至335美元
04-13 14:07
Jones Trading Initiates Coverage On AbCellera Biologics with Buy Rating, Announces Price Target of $11
Jones Trading analyst Debanjana Chatterjee initiates coverage on AbCellera Biologics (NASDAQ:ABCL) with a Buy rating and announces Price Target of $11.
04-10 20:20
Prelude Therapeutics Reports Full Year 2025 Financial Results and Provides Program Outlook for 2026
Prelude Therapeutics reported financial results for 2025, highlighting a cash runway extending into Q2 2027. The company announced FDA clearance for its mutant-selective JAK2V617F inhibitor PRT12396 and plans to initiate Phase 1 trials for PRT12396 in high-risk PV and MF patients in Q2 2026. Additionally, the KAT6A degrader PRT13722 is expected to enter clinical development later in 2026. Notably, R&D expenses decreased, reflecting reduced costs ...
03-10 11:01
AbCellera (ABCL) Earnings Call: Liquidity, Risks, Catalysts
Abcellera Biologics, Inc. (($ABCL)) has held its Q4 earnings call. Read on for ...
02-26 08:26
Why Axon Enterprise Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket
Shares of Axon Enterprise Inc (NASDAQ:AXON) rose sharply in pre-market trading ...
02-25 17:22
What Sparked AbCellera Biologics To Soar Over 9% After Hours
AbCellera Biologics shares jumped 9.3% after hours to $3.52 following an 83% earnings beat in Q4 2025.
02-25 16:51
AbCellera Biologics Q4 Earnings Report: What Investors Need to Know
The Q4 earnings report for AbCellera Biologics (NASDAQ:ABCL) was released on Tu...
02-25 05:22
Earnings Scheduled For February 24, 2026
Companies Reporting Before The Bell • China Yuchai Intl (NYSE:CYD) is expected ...
02-24 19:11
SoftBank adds TwentyOne Capital, exits Nvidia, boosts eToro stake among top Q4 trades
SoftBank Group (SFTBF) (SFTBY) added new stakes in TwentyOne Capital (XXI), closed out its holding in Nvidia (NVDA), increased its stake in trading platform eToro Group (ETOR), and pared its holding i...
02-18 00:39
